Investigating novel antibody drug conjugates for treating lung cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1126304

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Chemotherapy is first-line treatment for advanced lung cancer patients. Most patients inevitably develop chemotherapy resistance. To increase chemotherapy effectiveness, we are developing a new antibody-based approach to target cancer cells that die because of chemotherapy. The antibody is armed with a very potent drug released specifically at the cancer to cause death of surrounding, chemotherapy-resistant cells. Killing these cells may reduce rebound cancer growth and cause an immune reaction.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $663,447.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Biotechnology not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibody cancer therapy | biotechnology | drug conjugation | lung cancer | pre-clinical studies

Related Links